Skip to main content

Table 1 Percent distribution of selected characteristics at diagnosis in 1,204 women with invasive breast cancer

From: Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

 

All women

Younger women

Older women

(ages 35–49 y)

(ages 50–64 y)

 

White

Black

P a

White

Black

P a

White

Black

P a

 

n=681

n=523

 

n=345

n=272

 

n=336

n=251

 

Study site

  

0.01

  

0.07

  

0.09

 Los Angeles

66.7

73.2

 

64.9

71.7

 

68.5

74.9

 

 Detroit

33.3

26.8

 

35.1

28.3

 

31.6

25.1

 

Age at diagnosis, years

  

0.004

  

<0.001

   

 35-39

21.4

14.2

 

42.3

27.2

 

-

-

 

 40-44

15.9

19.5

 

31.3

37.5

 

-

-

 

 45-49

13.4

18.4

 

26.4

35.3

 

-

-

 

 50-54

18.7

17.6

 

-

-

 

37.8

36.7

0.42

 55-59

14.5

16.4

 

-

-

 

29.5

34.3

 

 60-64

16.2

14.0

 

-

-

 

32.7

29.1

 

ER status

  

<0.001

  

0.05

  

<0.001

 ER-

36.9

48.8

 

46.4

54.4

 

27.1

42.6

 

 ER+

63.1

51.2

 

53.6

45.6

 

72.9

57.4

 

PR status

  

<0.001

  

<0.001

  

<0.001

 PR-

38.5

52.4

 

42.6

54.0

 

34.2

50.6

 

 PR+

61.5

47.6

 

57.4

46.0

 

65.8

49.4

 

HER2 status

  

0.16

  

0.98

  

0.04

 HER2-

83.3

80.1

 

81.2

81.3

 

85.4

78.9

 

 HER2+

16.7

19.9

 

18.8

18.7

 

14.6

21.1

 

Subtypes defined by ER/PR/HER2

  

<0.001

  

0.12

  

<0.001

 TN

23.8

33.5

 

30.4

39.0

 

17.0

27.5

 

 Luminal A

59.5

46.7

 

50.7

42.3

 

68.5

51.4

 

 Luminal B

9.8

10.3

 

11.0

9.9

 

8.6

10.8

 

 HER2-enriched

6.9

9.6

 

7.8

8.8

 

6.0

10.4

 

p53 status

  

<0.001

     

0.003

 p53-

77.0

65.8

 

72.5

61.0

0.003

81.6

70.9

 

 p53+

23.0

34.2

 

27.5

39.0

 

18.4

29.1

 

Subtypes defined by ER/PR/HER2/p53

  

<0.001

  

0.03

  

<0.001

 TN/p53-

14.4

16.6

 

18.0

18.8

 

10.7

14.3

 

 TN/p53+

9.4

16.8

 

12.5

20.2

 

6.3

13.2

 

 Luminal A/p53-

49.9

37.7

 

41.5

31.3

 

58.6

44.6

 

 Luminal A/p53+

9.5

9.0

 

9.3

11.0

 

9.8

6.8

 

 Luminal B/p53-

8.1

6.0

 

8.4

5.2

 

7.7

6.8

 

 Luminal B/p53+

1.8

4.4

 

2.6

4.8

 

0.9

4.0

 

 HER2-enriched/p53-

4.6

5.5

 

4.6

5.9

 

4.5

5.2

 

 HER2-enriched/p53+

2.4

4.0

 

3.2

2.9

 

1.5

5.2

 

Stage

  

<0.001

  

0.007

  

0.001

 Localized

63.1

51.1

 

56.5

45.6

 

69.9

57.0

 

 Non-localized

36.9

49.0

 

43.5

54.4

 

30.1

43.0

 

Grade

  

<0.001

  

0.006

  

<0.001

 Low

12.5

8.6

 

9.6

6.6

 

15.5

10.8

 

 Intermediate

63.1

53.0

 

58.6

49.3

 

67.9

57.0

 

 High

24.4

38.4

 

31.9

44.1

 

16.7

32.3

 
  1. a P ascertained from Pearson χ2 test. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TN, triple negative. Note: TN = ER-/PR-/HER2-, Luminal A = ER+ or PR+ plus HER2-, Luminal B = ER+ or PR+ plus HER2+, HER2-enriched = ER-/PR-/HER2+.